Replidyne Phase II Pediatric Trial Meets Primary Objective

Wed, 07 Mar 2007 02:00 PM EST

... Replidyne, Inc. (Nasdaq: RDYN) announced today that it has completed its Phase II clinical trial using faropenem medoxomil (faropenem) in pediatric patients with acute otitis media (AOM), a common infection of the middle ear. [click link for full article] ...